Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma

As a multi-kinase inhibitor, sorafenib is beneficial in around 30% of hepatocellular carcinoma (HCC) patients; however, HCC patients develop acquired drug resistance quickly. Clinical benefits of sorafenib, in combination with transarterial chemoembolization (TACE), radiotherapy, and other chemodrug...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Yang, Xuran, Xia, Wei, Chen, Lin, Wu, Chuan Xing, Zhang, Cathy C., Olson, Peter, Wang, Xiao Qi
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2018
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201862/
https://ncbi.nlm.nih.gov/pubmed/30405889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26209
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki